U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Ho C, Spry C. Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis: A Review of the Clinical effectiveness, Cost-effectiveness, and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 May 17.

Cover of Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis: A Review of the Clinical effectiveness, Cost-effectiveness, and Guidelines

Rituximab for Granulomatosis with Polyangiitis or Microscopic Polyangiitis: A Review of the Clinical effectiveness, Cost-effectiveness, and Guidelines [Internet].

Show details

Context and Policy Issues

Granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) belong to a group of rare autoimmune diseases called anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis, characterized by inflammatory cell infiltration leading to necrosis of the blood vessels. 1,2

Treatment of GPA and MPA includes remission induction and remission maintenance. Currently, rituximab, a monoclonal antibody, is one of the therapeutic options approved for the induction phase.1,3,4 Recently, a number of uncontrolled studies have suggested that rituximab can also be of value in maintaining remission. 5-10

This Rapid Response report aims to review the clinical effectiveness of rituximab compared to other immunosuppressive drugs. Cost-effectiveness and evidence-based guidelines regarding the use of rituximab for patients with GPA and MPA will also be examined. This review is an update of a previous CADTH review that found no evidence on the comparative clinical effectiveness of rituximab for remission maintenance in patients with GPA and MPA.11

Copyright © 2017 Canadian Agency for Drugs and Technologies in Health.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

Bookshelf ID: NBK481991
Contents

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (273K)

Other titles in this collection

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...